Kalydeco: new treatment option for cystic fibrosis

Kalydeco (ivacaftor) is licensed for the treatment of cystic fibrosis in patients aged six years and over with a G551D mutation in the CFTR gene.

The recommended dose of Kalydeco is 150mg every 12 hours with fat-containing food.
The recommended dose of Kalydeco is 150mg every 12 hours with fat-containing food.


Ivacaftor is a selective potentiator of the CFTR protein. It increases CFTR channel gating to enhance chloride transport.1 


In two randomised, double-blind, phase III trials in 213 patients with the G551D mutation on at least one allele of the CFTR gene and forced expiratory volume in one second (FEV1) ≥40%, ivacaftor led to a rapid (15 days) improvement in FEV1. The treatment difference between ivacaftor and placebo for mean absolute change in per cent predicted FEV1 from baseline to week 24 was 10.6 percentage points in patients aged 12 years or older and 12.5 percentage points in patients aged 6 to 11 years.1


  1.  Kalydeco Summary of Product Characteristics, August 2012.

View Kalydeco record

Further information: Vertex Pharmaceuticals

Follow MIMS on Twitter 

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases